Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials

JCO The initial STOMP and ORIOLE trial reports suggested that metastasis-directed therapy (MDT) in oligometastatic castration-sensitive prostate cancer (omCSPC) was associated with improved treatment outcomes. Here, we present long-term outcomes of MDT in omCSPC by pooling STOMP and ORIOLE and assess the ability of a high-risk mutational signature to risk stratify outcomes after MDT. The primary end point was progression-free survival (PFS) calculated using the Kaplan-Meier method. High-risk mutations were defined as pathogenic somatic mutations within , /, , or . The median follow-up for the whole group was 52.5 months. Median PFS was prolonged with MDT compared with observation (pooled hazard ratio [HR], 0.44; 95% CI, 0.29 to 0.66; value < .001), with the largest benefit of MDT in patients with a high-risk mutation (HR high-risk, 0.05; HR no high-risk, 0.42; value for interaction: .12). Within the MDT cohort, the PFS was 13.4 months in those without a high-risk mutation, compared with 7.5 months in those with a high-risk mutation (HR, 0.53; 95% CI, 0.25 to 1.11; = .09). Long-term outcomes from the only two randomized trials in omCSPC suggest a sustained clinical benefit to MDT over observation. A high-risk mutational signature may help risk stratify treatment outcomes after MDT.

Citing Articles

TP53 Deficiency in the Natural History of Prostate Cancer.

Ofner H, Kramer G, Shariat S, Hassler M Cancers (Basel). 2025; 17(4).

PMID: 40002239 PMC: 11853097. DOI: 10.3390/cancers17040645.

Defining The Role for Hormone Therapy in Biochemically Recurrent Prostate Cancer: What Counts as a Win for Patients?.

OLoughlin L, Abel M, Madan R, Einstein D Curr Oncol Rep. 2025; .

PMID: 39985705 DOI: 10.1007/s11912-025-01647-5.

Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment. A subgroup analysis from ARTO trial (NCT03449719).

Francolini G, Bertini N, Di Cataldo V, Garlatti P, Aquilano M, Caini S Prostate Cancer Prostatic Dis. 2025; .

PMID: 39972049 DOI: 10.1038/s41391-025-00950-3.

Long-term survival and undetectable circulating tumor DNA following comprehensive involved site radiotherapy for oligometastases.

Radigan R, Kao C, Krainock M, Liu M, Gupta V, Alexander L Sci Rep. 2025; 15(1):6126.

PMID: 39971963 PMC: 11839900. DOI: 10.1038/s41598-025-88266-z.

Stereotactic ablative radiotherapy (SABR) for pelvic nodal oligorecurrence in prostate cancer.

Lopez-Valcarcel M, Valcarcel F, Velasco J, Zapata I, Rodriguez R, Cardona J Rep Pract Oncol Radiother. 2025; 29(4):445-453.

PMID: 39895963 PMC: 11785391. DOI: 10.5603/rpor.101528.

References

Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A . Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol. 2017; 36(5):446-453. DOI: 10.1200/JCO.2017.75.4853. View

Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M . Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013; 31(14):1748-57. PMC: 3641696. DOI: 10.1200/JCO.2012.43.1882. View

Lussier Y, Rosie Xing H, Salama J, Khodarev N, Huang Y, Zhang Q . MicroRNA expression characterizes oligometastasis(es). PLoS One. 2011; 6(12):e28650. PMC: 3236765. DOI: 10.1371/journal.pone.0028650. View

Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I . Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci U S A. 2019; 116(23):11428-11436. PMC: 6561293. DOI: 10.1073/pnas.1902651116. View

Onderdonk B, Gutiontov S, Chmura S . The Evolution (and Future) of Stereotactic Body Radiotherapy in the Treatment of Oligometastatic Disease. Hematol Oncol Clin North Am. 2019; 34(1):307-320. DOI: 10.1016/j.hoc.2019.09.003. View

Hasan H, Deek M, Phillips R, Hobbs R, Malek R, Radwan N . A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS). BMC Cancer. 2020; 20(1):492. PMC: 7268477. DOI: 10.1186/s12885-020-07000-2. View

Deek M, Van der Eecken K, Phillips R, Parikh N, Velho P, Lotan T . The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. Eur Urol. 2021; 80(5):632-640. PMC: 10262980. DOI: 10.1016/j.eururo.2020.12.040. View

Pitroda S, Weichselbaum R . Integrated molecular and clinical staging defines the spectrum of metastatic cancer. Nat Rev Clin Oncol. 2019; 16(9):581-588. DOI: 10.1038/s41571-019-0220-6. View

Van der Eecken K, Vanwelkenhuyzen J, Deek M, Tran P, Warner E, Wyatt A . Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review. Eur Urol Oncol. 2021; 4(6):914-923. DOI: 10.1016/j.euo.2021.10.005. View

10.

Lussier Y, Khodarev N, Regan K, Corbin K, Li H, Ganai S . Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One. 2012; 7(12):e50141. PMC: 3518475. DOI: 10.1371/journal.pone.0050141. View

11.

Pitroda S, Khodarev N, Huang L, Uppal A, Wightman S, Ganai S . Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nat Commun. 2018; 9(1):1793. PMC: 5935683. DOI: 10.1038/s41467-018-04278-6. View

12.

Phillips R, Shi W, Deek M, Radwan N, Lim S, Antonarakis E . Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol. 2020; 6(5):650-659. PMC: 7225913. DOI: 10.1001/jamaoncol.2020.0147. View

13.

Gallagher D, Gaudet M, Pal P, Kirchhoff T, Balistreri L, Vora K . Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res. 2010; 16(7):2115-21. PMC: 3713614. DOI: 10.1158/1078-0432.CCR-09-2871. View

14.

Wong A, Watson S, Pitroda S, Son C, Das L, Stack M . Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer. 2016; 122(14):2242-50. DOI: 10.1002/cncr.30058. View

15.

Karlsson Q, Brook M, Dadaev T, Wakerell S, Saunders E, Muir K . Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. Eur Urol Oncol. 2021; 4(4):570-579. PMC: 8381233. DOI: 10.1016/j.euo.2020.12.001. View